The Therapeutic Potential of RNA M(6)A in Lung Cancer

Overview

Journal Cell Commun Signal

Publisher Biomed Central

Specialties Biochemistry
Cell Biology

Date 2024 Dec 30

PMID 39736743

Authors

Jingran Yu

Wei Sun

Xiangxuan Zhao

Yingying Chen

Affiliations

Soon will be listed here.

Abstract

Lung cancer (LC) is a highly malignant and metastatic form of cancer. The global incidence of and mortality from LC is steadily increasing; the mean 5-year overall survival (OS) rate for LC is less than 20%. This frustrating situation may be attributed to the fact that the pathogenesis of LC remains poorly understood and there is still no cure for mid to advanced LC. Methylation at the N-position of adenosine (NmA) of RNA (m(6)A) is widely present in human tissues and organs, and has been found to be necessary for cell development and maintenance of homeostasis. However, numerous basic and clinical studies have demonstrated that RNA m(6)A is deregulated in many human malignancies including LC. This can drive LC malignant characteristics such as proliferation, stemness, invasion, epithelial-mesenchymal transition (EMT), metastasis, and therapeutic resistance. Intriguingly, an increasing number of studies have also shown that eliminating RNA m(6)A dysfunction can exert significant anti-cancer effects on LC such as suppression of cell proliferation and viability, induction of cell death, and reversal of treatment insensitivity. The current review comprehensively discusses the therapeutic potential of RNA m(6)A and its underlying molecular mechanisms in LC, providing useful information for the development of novel LC treatment strategies.

References

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Wu K, Lin K, Li X, Yuan X, Xu P, Ni P . Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment. Front Immunol. 2020; 11:1731. PMC: 7417513. DOI: 10.3389/fimmu.2020.01731. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Gould M, Creekmur B, Qi L, Golden S, Kaplan C, Walter E . Emotional Distress, Anxiety, and General Health Status in Patients With Newly Identified Small Pulmonary Nodules: Results From the Watch the Spot Trial. Chest. 2023; 164(6):1560-1571. DOI: 10.1016/j.chest.2023.06.022. View

Shi L, Gong Y, Zhuo L, Wang S, Chen S, Ke B . Methyltransferase-like 3 upregulation is involved in the chemoresistance of non-small cell lung cancer. Ann Transl Med. 2022; 10(3):139. PMC: 8904991. DOI: 10.21037/atm-21-6608. View

Wu X, Sui Z, Zhang H, Wang Y, Yu Z . Integrated Analysis of lncRNA-Mediated ceRNA Network in Lung Adenocarcinoma. Front Oncol. 2020; 10:554759. PMC: 7523091. DOI: 10.3389/fonc.2020.554759. View

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

Shigeyasu K, Toden S, Ozawa T, Matsuyama T, Nagasaka T, Ishikawa T . The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer. Mol Cancer. 2020; 19(1):155. PMC: 7643275. DOI: 10.1186/s12943-020-01277-4. View

Mamdani H, Matosevic S, Khalid A, Durm G, Jalal S . Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Front Immunol. 2022; 13:823618. PMC: 8864096. DOI: 10.3389/fimmu.2022.823618. View

10.

Hou G, Zhao X, Li L, Yang Q, Liu X, Huang C . SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs. Nucleic Acids Res. 2021; 49(5):2859-2877. PMC: 7969013. DOI: 10.1093/nar/gkab065. View

11.

Zheng W, Feng Q, Liu J, Guo Y, Gao L, Li R . Inhibition of 6-phosphogluconate Dehydrogenase Reverses Cisplatin Resistance in Ovarian and Lung Cancer. Front Pharmacol. 2017; 8:421. PMC: 5491617. DOI: 10.3389/fphar.2017.00421. View

12.

Zeng C, Huang W, Li Y, Weng H . Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020; 13(1):117. PMC: 7457244. DOI: 10.1186/s13045-020-00951-w. View

13.

Odogwu L, Mathieu L, Blumenthal G, Larkins E, Goldberg K, Griffin N . FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring Mutations. Oncologist. 2018; 23(6):740-745. PMC: 6067947. DOI: 10.1634/theoncologist.2017-0642. View

14.

Zhang Y, Liu S, Zhao T, Dang C . METTL3‑mediated m6A modification of Bcl‑2 mRNA promotes non‑small cell lung cancer progression. Oncol Rep. 2021; 46(2). PMC: 8218297. DOI: 10.3892/or.2021.8114. View

15.

Wang F, Zhang J, Lin X, Yang L, Zhou Q, Mi X . METTL16 promotes translation and lung tumorigenesis by sequestering cytoplasmic eIF4E2. Cell Rep. 2023; 42(3):112150. DOI: 10.1016/j.celrep.2023.112150. View

16.

Zhu W, Wang J, Xu Z, Cao M, Hu Q, Pan C . Detection of N6‑methyladenosine modification residues (Review). Int J Mol Med. 2019; 43(6):2267-2278. PMC: 6488182. DOI: 10.3892/ijmm.2019.4169. View

17.

Cui Y, Wu Y, Wang C, Wang Z, Li Y, Jiang Z . Isoliquiritigenin inhibits non-small cell lung cancer progression via mA/IGF2BP3-dependent TWIST1 mRNA stabilization. Phytomedicine. 2022; 104:154299. DOI: 10.1016/j.phymed.2022.154299. View

18.

Linder B, Grozhik A, Olarerin-George A, Meydan C, Mason C, Jaffrey S . Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat Methods. 2015; 12(8):767-72. PMC: 4487409. DOI: 10.1038/nmeth.3453. View

19.

Zhang W, Wu T, Zhang Y, Kang W, Du C, You Q . Targeting mA binding protein YTHDFs for cancer therapy. Bioorg Med Chem. 2023; 90:117373. DOI: 10.1016/j.bmc.2023.117373. View

20.

Oliveira R, Guedes R, Salvador J . Highlights in USP7 inhibitors for cancer treatment. Front Chem. 2022; 10:1005727. PMC: 9520255. DOI: 10.3389/fchem.2022.1005727. View